Three month FVC change: a potential trial endpoint for IPF based on individual participant data meta-analysis

RationaleNovel therapies for idiopathic pulmonary fibrosis (IPF) are in development, but there remains uncertainty about the optimal trial endpoint. An earlier endpoint would enable assessment of a greater number of therapies in adaptive trial designs. ObjectivesIndividual participant data (IPD) from placebo arms of interventional trials were sought to determine whether short-term... Show more